Doris K. Hansen

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Doris K. Hansen, Surbhi Sidana, Lauren C. Peres et al. · Journal of Clinical Oncology · 2023 · 257 citations · Full text

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi et al. · Blood Cancer Journal · 2023 · 96 citations · Full text

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

Kai Rejeski, Doris K. Hansen, Radhika Bansal et al. · Journal of Hematology & Oncology · 2023 · 95 citations · Full text

Hematological Malignancy, Car-hematotox Score, Medicine +9

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Jennifer M. Logue, Lauren C. Peres, Hamza Hashmi et al. · Blood Advances · 2022 · 94 citations · Full text

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Surbhi Sidana, Krina K. Patel, Lauren C. Peres et al. · Blood · 2024 · 92 citations · Full text